Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An announcement from Amoeba SA ( (FR:ALMIB) ) is now available.
Amoéba announced the final evaluation report from the European Food Safety Authority (EFSA), which confirms the effectiveness and low-risk profile of its biocontrol active substance. This positive assessment allows Amoéba to proceed with market authorization applications in Europe for its biocontrol products, branded as ‘AXPERA,’ targeting eight European member states. The European Commission has six months to ratify the approval, and commercialization is anticipated by the end of 2025. Additionally, Amoéba is awaiting a decision from the US Environmental Protection Agency for its ‘AXPERA’ range, expected by mid-2025. This development positions Amoéba to enhance its market presence and offers potential growth opportunities in both the European and US markets.
More about Amoeba SA
Founded in 2010, Amoéba is a greentech company based in Chassieu, France, focusing on the development of natural microbiological solutions for the plant protection and cosmetic sectors. Utilizing the Willaertia amoeba, Amoéba offers biological alternatives to chemical products, aiming to become a significant player in the microbiological risk treatment industry. The company is listed on Euronext Growth and is a member of the Bpifrance Excellence network.
YTD Price Performance: -13.66%
Average Trading Volume: 1,487
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €40.32M
For an in-depth examination of ALMIB stock, go to TipRanks’ Stock Analysis page.
